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Abstract: As new biomarkers, circular RNAs (circRNAs) have been largely unexplored in prostate 
cancer (PCa). Using an integrative approach, we aimed to evaluate the potential of circRNAs and 
their linear transcripts (linRNAs) to act as (i) diagnostic biomarkers for differentiation between 
normal and tumor tissue and (ii) prognostic biomarkers for the prediction of biochemical recurrence 
(BCR) after radical prostatectomy. In a first step, eight circRNAs (circATXN10, circCRIM1, 
circCSNK1G3, circGUCY1A2, circLPP, circNEAT1, circRHOBTB3, and circSTIL) were identified as 
differentially expressed via a genome-wide circRNA-based microarray analysis of six PCa samples. 
Additional bioinformatics and literature data were applied for this selection process. In total, 115 
malignant PCa and 79 adjacent normal tissue samples were examined using robust RT-qPCR assays 
specifically established for the circRNAs and their linear counterparts. Their diagnostic and 
prognostic potential was evaluated using receiver operating characteristic curves, Cox regressions, 
decision curve analyses, and C-statistic calculations of prognostic indices. The combination of 
circATXN10 and linSTIL showed a high discriminative ability between malignant and adjacent 
normal tissue PCa. The combination of linGUCY1A2, linNEAT1, and linSTIL proved to be the best 
predictive RNA-signature for BCR. The combination of this RNA signature with five established 
reference models based on only clinicopathological factors resulted in an improved predictive 
accuracy for BCR in these models. This is an encouraging study for PCa to evaluate circRNAs and 
their linRNAs in an integrative approach, and the results showed their clinical potential in 
combination with standard clinicopathological variables. 
Int. J. Mol. Sci. 2020, 21, 7812 2 of 32 
 
Keywords: prostate cancer; microarray; identification; validation and differential expression of 
circular RNAs; circular RNAs and linear counterparts; biochemical recurrence; diagnostic and 
prognostic tissue biomarkers; improved predictive accuracy by RNA signature 
 
1. Introduction 
Prostate cancer (PCa) is the second most common cancer type among men [1]. Following radical 
prostatectomy, which is used as a therapeutic curative option for patients suffering from PCa, 
biochemical recurrence (BCR), defined as a re-increased serum concentration of prostate-specific 
antigen (PSA) of >0.2 µg/L [2,3], is clinically considered to be the first sign of disease recurrence [4,5]. 
An evaluation of six recent studies with more than 1000 patients in each showed that approximately 
15–34% of surgically treated patients suffered from BCR within 5 to 10 years after surgery [6]. 
Following BCR without secondary therapy, distant metastasis manifests in approximately 30% of 
patients and 19–27% will die within 10 years [7,8]. These data clearly show that early and reliable 
prediction of patients with a high risk of BCR is necessary to optimize the frequency of follow-up and 
thus the decision to undergo adjuvant therapy. 
For BCR risk prediction, numerous scoring systems based on clinicopathological factors such as 
the Gleason score or the respective International Society of Urological Pathology (ISUP) grade, 
pathological tumor stage (pT stage), and preoperative PSA level are currently applied. Among these 
tools are the Cancer of the Prostate Risk Assessment Postsurgical Score (CAPRAS) [9] and those 
developed by D’Amico et al. [10], Stephenson et al. [7], and the National Comprehensive Cancer 
Network (NCCN) [11]. Although all clinicopathological factors are, to some extent, associated with 
patient outcome, the prognostic accuracy of these nomograms is generally unsatisfactory [12–16]. In 
this context, prognostic molecular biomarkers could significantly improve the predictive accuracy of 
tools based only on clinicopathological factors [17–21]. We recently elaborated a five-microRNA 
signature that outperforms the BCR scoring systems mentioned above [6]. In addition, the combined 
use of clinicopathological factors and molecular markers was found to significantly improve the 
predictive accuracy compared to the separately calculated predictive value [6]. Based on this 
experience using molecular markers in BCR prediction, we decided to extend this approach to 
circular RNAs (circRNA), which we successfully introduced as prognostic biomarkers in clear cell 
renal cell carcinoma [22]. 
Recently, circRNAs have the subject of increasing interest in medicine. These RNAs consist of a 
single strand of RNA in a closed loop [23,24], and are formed by alternative splicing of mostly exonic 
sequences. One host gene can form several different circRNAs [25,26]. The functions of circRNAs are 
still being investigated. Their ability to sponge microRNAs (miRNAs), a process in which circRNAs 
prevent the inhibitory properties of miRNA and therefore promote the expression of target mRNAs, 
is relatively well known [23,24,27]. Furthermore, circRNAs may regulate the expression of their 
parenteral genes by interacting with RNA polymerase II [28], but they can also interact with RNA-
binding proteins and are therefore involved in the regulation of gene expression [29]. Some circRNAs 
may even be able to encode proteins [30]. CircRNAs have expression patterns that are specific to 
different cells or tissues and have been shown to play roles in cell regulation, including physiological 
as well as pathological processes [24,31–35]. It has been shown that circRNAs can act as oncogenes 
and tumor suppressors in the initiation and progression of different cancers, e.g., hepatocellular 
carcinoma, gastric carcinoma, colorectal cancer, and renal cell carcinoma [22,36–39]. All of these 
aspects justify a particular interest in using circRNAs as biomarkers in diagnosis, prognosis, and 
prediction, as well as for therapeutic targets [33,40–43]. 
CircRNAs in PCa are also a subject of present research. Last year, Chen et al. [44] identified a 
broad signature of PCa-specific circRNAs via ultra-deep rRNA-depleted RNA sequencing of 
localized PCa tissue samples. Moreover, specific circRNA functions were shown. CircCSNK1G3, for 
example, seems to promote cell proliferation in PCa [44]. Furthermore, Zhang et al. [45] applied a 
bioinformatics approach using various PCa cells to identify numerous circRNAs, including 
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circGUCY1A2, as potential candidates for PCa progression. Other working groups using microarray 
platforms have reported lists of the top up- and downregulated circRNAs in PCa tissue compared 
with adjacent normal tissue [46,47]. Recent studies have particularly analyzed functional features and 
underlying molecular mechanisms of individual circRNAs [48–53]. Several publications particularly 
focused on androgen receptor pathway related circRNAs [54–57]. Correlations between the 
expression of circRNAs and relevant clinicopathological factors or survival Kaplan-Meier analyses 
have been reported [44,51,58–62]. However, it is astonishing that the potential of circRNAs as 
diagnostic and prognostic tissue biomarkers has so far only been evaluated in isolated cases 
[47,58,61]. As far as we know, only one study has ever conducted multivariate analyses of circRNAs 
in connection with clinicopathological factors [61]. Studies on the clinical validity of circRNAs in 
relation to BCR are still lacking. 
Thus, in this study, we aimed to (i) identify differentially expressed circRNAs in six paired 
samples of PCa tissue and adjacent normal tissue using microarray analysis, (ii) validate the 
differential expression of eight chosen circRNAs and their linear counterparts via reverse-
transcription quantitative real-time polymerase chain reaction (RT-qPCR), (iii) examine the 
differentiating potential between malignant and non-malignant prostate tissue in 194 samples of 115 
PCa patients including 79 paired samples, and (iv) evaluate the potential of the chosen circRNAs and 
their linear counterparts as biomarkers in combination with the clinicopathological factors of PCa 
patients after radical prostatectomy to predict BCR. 
2. Results 
2.1. Patient Characteristics and Study Design 
One hundred and fifteen untreated PCa patients who underwent radical prostatectomy between 
2007 and 2014 with follow-up data until November 2019 were included in this study. Follow-up data 
were based on medical records and telephone contacts with the patients, their physicians, and their 
family members. In total, 194 tissue samples with 79 pairs of adjacent normal and malignant samples, 
and 36 with malignant characteristics only were investigated (Table 1). The sample size was 
determined using a power-adapted calculation (α = 5%, power = 80%; Supplementary Information S1 
(Supplementary Materials)). A two-to-one selection of available samples, based on patients with BCR, 
was retrospectively performed with 76 patients without BCR and 39 with BCR. BCR was defined as 
a postoperative PSA increase above 0.2 µg/L after radical prostatectomy, as confirmed by consecutive 
increased values [2,3]. The workflow diagram presented in Figure 1 outlines the design of this study, 
which involved three phases based on the above postulated objectives for this investigation: (i) the 
discovery phase of identifying differentially expressed circRNAs using a microarray screening 
approach and the selection of circRNAs for further evaluation; (ii) analytical confirmation of the 
circular nature of selected circRNAs and elaboration of “fit-for-purpose” RT-qPCR assays for 
circRNAs and their linear transcripts; and (iii) initial clinical evaluations regarding their validity as 
discriminative tissue classifiers and the predictive value of these biomarkers when applied alone and 
in combination with conventional clinicopathological factors. 
Table 1. Clinicopathological characteristics of the study group. 








Patients, no. (%) 115 (100) 39 (34) 76 (66)  
Age, median years, (IQR) 67 (62–70) 66 (59–71) 67 (64–70) 0.339 
PSA, µg/L (IQR) 7.7 (5.4–12.2) 9.7 (6.1–19.5) 7.0 (5.4–9.5) 0.011 
Prostate volume, cm3 (IQR) 32 (25–45) 30 (23–39) 33 (26–45) 0.264 
DRE, no. (%)    0.067 
Non-suspicious 67 (58) 17 (44) 50 (66)  
Suspicious 32 (28) 14 (36) 18 (24)  
Unclassified 16 (14) 8 (20) 8 (10)  
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pT status, no. (%)    0.005 
pT1c 1 (1) 0 1 (1)  
pT2a 2 (2) 0 2 (3)  
pT2b 1 (1) 0 1 (1)  
pT2c 61 (53) 13 (33) 48 (63)  
pT3a 27 (23) 11 (28)  16 (21)  
pT3b 23 (20) 15 (39) 8 (11)  
ISUP Grade groups, no. (%)    0.0001 
1 26 (23) 2 (5) 24 (31)  
2 47 (41) 13 (33) 34 (45)  
3 30 (26) 14 (36) 16 (21)  
4 4 (3 4 (11) 0 (0)  
5 8 (7) 6 (15) 2 (3)  
pN status, no. (%)    0.017 
pN0/Nx 109 (95) 34 (87) 75 (99)  
pN1 6 (5) 5 (13) 1 (1)  
Surgical margin, no. (%)     
Negative 64 (56) 16 (41) 48 (63) 0.030 
Positive 51 (44) 23 (59) 28 (37)  
Follow-up after surgery    < 0.0001 
Median months (IQR) 41 (26–72) 19.9 (9.8–41) 52 (38–80)  
Abbreviations: CI, confidence interval; DRE, digital rectal examination; IQR, interquartile range; ISUP 
Grade groups, histopathological grade system based on Gleason score according to the International 
Society of Urologic Pathology; pN, lymph node status; PSA, total prostate specific antigen before 
surgery; pT, pathological tumor classification. a p-Values (Mann-Whitney U test; Chi-square or 
Fisher’s exact test) indicate the association of the clinicopathological variables with patients with and 
without biochemical recurrence. 
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Figure 1. Workflow of the study in three phases. Abbreviations: circRNA, circular RNA; PCa, prostate 
cancer; RT-qPCR, reverse-transcription quantitative real-time polymerase chain reaction. 
2.2. Discovery of circRNAs in Prostate Cancer Tissue Using Microarray Analysis 
2.2.1. Identification of Differentially Expressed circRNAs 
Six matched PCa tissue samples were examined using ArrayStar microarray experiment. A total 
of 9599 circRNAs out of 13,617 distinct probes on the array were detected (Supplementary Microarray 
Data File.xlsx (Supplementary Materials)). This number of circRNAs derived from 4838 host genes, 
since numerous host genes can form multiple circRNA isoforms [26]. Approximately 26% of all 
detected circRNAs were found to be from ~50% of the host genes that form only one circRNA, while 
the other 41% of circRNAs were found from the ~35% of the host genes that can form two or three 
circRNAs. Approximately 3.2% of the circRNAs were derived from only 0.6% of the host genes able 
to form 10 or more circRNAs (Figure 2A). Different genomic regions can be the origin of circRNAs. 
In this PCa microarray screening, approximately 90% of circRNAs were of exonic origin, but intronic, 
sense-overlapping, anti-sense, and intergenic circRNA types were also detected (Figure 2B). These 
data correspond with our own results in renal cell carcinoma [22] and data from studies on other 
tissues [25]. Regarding the differential expression between adjacent normal and malignant tissue, the 
array data identified 43 upregulated and 134 downregulated circRNAs with a higher than absolute 
1.5-fold change (p < 0.05) in malignant tissue samples (Figure 2C). Using a threshold of 2-fold change, 
only six upregulated and 18 downregulated circRNAs were identified. Based on a principal 
component analysis of the microarray expression data, two separate clusters with malignant and 
adjacent normal tissue characteristics were ascertained (Figure 2D). 
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Figure 2. Microarray analysis results of six matched prostate cancer (PCa) tissue samples. (A) The 
number of circular RNAs (circRNAs) expressed per host gene in the malignant tissue samples and 
their matched adjacent normal tissue samples from PCa specimens after prostatectomy. (B) Genomic 
origin of the detected circRNAs on the microarray. (C) Volcano plot with the up- and downregulated 
circRNAs in malignant vs. adjacent normal tissue samples. The dashed lines indicate the thresholds: 
absolute 1.5-fold changes and p-values of 0.05 in the t-test. The eight circRNAs that were selected for 
further evaluation in this study are marked. (D) Results of the principal component analysis with the 
left cluster of tumor samples (PCa1–PCa6, marked in blue) and the right cluster with the paired 
adjacent normal tissue samples (N1–N6, marked in brown). 
2.2.2. Selection of circRNAs for Further Evaluation 
In addition to the microarray-based expression results (absolute fold-change >1.5 with unadjusted 
p < 0.05 and sufficiently raw intensity on the microarray), we used interest-specific criteria to select 
circRNAs for further investigation. We selected six circRNAs (Table 2), for which no information on 
prostate carcinoma was available. Their host genes had been described in individual studies with 
regard to their roles in either PCa progression (e.g., CRIM1, NEAT1, and STIL [63–65]) or other 
cancers (e.g., LPP and RHOBTB3 [66,67]). Some of the selected circRNAs had been partly identified 
in other cancers (e.g., circCRIM1 and circRHOBTB3 [22,68]). Finally, an in silico analysis of miRNA 
interaction with these circRNAs was performed using the algorithm provided by the CircInteractome 
tool and the miRDB and TargetScan databases [69–71]. In all cases, the circRNAs were found to be 
crucial points for potentially relevant miRNA–gene interactions (Figure S1). This also fulfilled a 
selection criterion for further investigations to be planned. NEAT1 was identified as a special case 
because it already has miRNA-sponging functions as a long non-coding RNA (lncRNA) [65]. Thus, 
the relationship between the circRNA and the lncRNA transcript was of particular interest. In this 
circRNA panel, two additional circRNAs from the genes CSNK1G3 and GUCY1A2 were included as 
these circRNAs were recently identified in PCa tissue samples and PCa cell lines as mentioned in the 
introduction [44,45]. Collectively, the microarray analysis of the six paired samples in the discovery 
phase (Figure 1) must be considered an exploratory study for ranking deregulated circRNAs using 
the unadjusted p-values supported by the mentioned additional selection criteria. Under these 
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conditions, an exploratory study should be preferably analyzed without p-value adjustment, but 
needs a technical replication by a different assay technique and biological validation using other 
clinical samples [72–74]. This was done in the two subsequent workflow phases B and C (Figure 1). 
Data on the selected circRNAs are given in Table 2. Currently, there is no standardized 
nomenclature for circRNAs [22], and the designations of the database circBase are mainly used as a 
reference [75]. In order to facilitate the readability of the manuscript, official gene symbols with the 
prefixes “circ” and “lin” are used herein to characterize our selected circRNAs and the corresponding 
linear transcripts from the same host gene (Table 2). 
Table 2. List of circular RNAs (circRNAs) seleceted for further evaluation in this study based on their 
differential expression between malignant and adjacent normal tissue samples data in the microarray 
discovery study phase and literature search. 
circRNA in 
Manuscript 







Official Gene Symbol 
(Official Gene Name) 
Upregulated circRNAs 
circLPP circ_0003759 1.94 (0.025) NM_005578.5 
LPP 
(LIM domain containing preferred translocation 
partner in lipoma) 
circNEAT1 circ_0000324 2.73 (0.0235) NR_131012.1 
NEAT1 
(Nuclear paraspeckle assembly transcript 1) 
circSTIL circ_0000069 1.75 (0.007) NM_001282936.1 
STIL 
(STIL centriolar assembly protein) 
Downregulated circRNAs 
circATXN10 circ_0001246 2.48 (0.001)) NM_013236.4 
ATXN10 
(Ataxin 10) 
circCRIM1 circ_0007386 2.17 (0.006)) NM_016441.3 
CRIM1 
(Cysteine rich transmembrane BMP regulator 1) 
circRHOBTB3 circ_0007444 2.14 (0.0003) NM_014899.4 
RHOBTB3 
(Rho related BTB domain containing 3) 
circRNAs from Literature c 
circCSNK1G3 circ_0001522 −1.31 (0.003) NM_001044723.2 
CSNK1G3 
(Casein kinase 1 gamma 3) 
circGUCY1A2 circ_0008602 −1.02 (0.305) NM_000855.3 
GUCY1A2 
(Guanylate cyclase 1 soluble subunit alpha 2) 
a The obligatory prefix hsa_ was omitted to facilitate the readability. b In the separate Supplementary 
Microarray Data File.xlsx as part of the Supplementary Materials, detailed information is given for all 
detected circRNAs including source, chromosome localization, strand, circRNA type, sequences, and 
the circRNA IDs specific for ArrayStar Microarrays and the database circBase [75]. c Chen et al. [44] 
for circCSNK1G3 and Zhang et al. [45] for circGUCY1A2. 
2.3. Analytical Confirmation Phase of the Selected circRNAs 
2.3.1. Experimental Proof of the Circular Nature of Transcripts 
RT-qPCR assays using SYBRGreen I were established for the eight selected circRNAs and their 
linear counterparts, taking into account the MIQE guidelines “Minimum Information for Publication 
of Quantitative Real-Time PCR Experiments” [76] (Supplementary Information S3 (Supplementary 
Materials) with the Tables S1–S7 in addition to Section 4 of this paper). Experimental confirmation of 
the circular nature of the identified circRNAs via microarray and sequencing technologies was 
achieved using different tests to confirm the characteristics of the circRNA-specific backsplice 
junction [24,77,78]. Figure 3 shows that circRNAs are resitant to RNase R digestion (Figure 3A), 
distinctly decreased complementary DNA (cDNA) synthesis occurred when oligo(dT)18 primers were 
used compared with when random hexamer primers (Figure 3B) were used, and the backsplice 
junction was confirmed by Sanger sequencing (Figure 3C). Melting curve analysis and 
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electrophoresis of the amplicons were applied in order to validate the analytical specificity of the RT-
qPCR products in all assays (Figures S2, S3, and Table S7). 
 
Figure 3. Experimental proof of the circular nature of the circRNAs selected in this study. (A) 
Resistance of circRNAs to RNase R digestion compared with linear RNAs. Data for triplicates (mean 
± standard deviation) normalized to controls without RNase treatment are presented. (B) Decreased 
cDNA synthesis of circRNAs with oligo(dT)18 vs. random hexamer primers. Data are given as the 
relative expression normalized to hexamer-primers-based cDNA synthesis. The relative expression 
was markedly decreased in all circRNAs (at least n = 3 of tissue pools) when using oligo(dT)18 primers 
in comparison to random hexamer primers, indicating that the circRNAs lacked a poly(A) tail. (C) 
Base sequence of circRNA backsplice junction pictured by Sanger sequencing. CircLPP, circNEAT1, 
and circSTIL were only sequenced in one direction as one of the primers was junction-spanning (Table 
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S3). The sequencing result of circRHOBTB3 corresponded to that in kidney carcinoma [22]. 
Methodical details for all experiments listed here are described in Section 4 and Supplementary 
Information S4 (Supplementary Materials). 
2.3.2. Analytical Performance of RT-qPCR Assays 
According to the MIQE guidelines [76] and also to the “Standards for Reporting of Diagnostic 
Accuracy Studies” (STARD) [79], the repeatability (intra-assay variation) and reproducibility (inter-
assay variation) of the measurements should be used decisive criteria for the performance and 
robustness of RT-qPCR tests. Supported by the analytical specificity of the established assays (Figures 
S2 and S3) and the characteristics of the PCR standard curves (Table S7), the data shown in Table 3 
proved that the assays were suitable for “fit-for-purpose” RT-qPCR measurements in clinical studies 
[80]. An exception was circNEAT1, which had rather poor repeatability and reproducibility due to its 
very low expression. 
Table 3. Repeatability and reproducibility of RT-qPCR measurements. 
RNA 






Mean ± SD (%RSD) 
Relative Quantities 
Mean ± SD (%RSD) 
circATXN10 24.49 (0.595) 1.345 (10.4) 24.31 ± 0.144 (0.591) 1.004 ± 0.100 (9.98) 
circCRIM1 24.61 (0.455) 1.299 (7.59) 24.39 ± 0.115 (0.472) 1.003 ± 0.078 (7.79) 
circCSNK1G3 21.47 (0.289) 1.164 (4.28) 21.34 ± 0.131 (0.613) 1.003 ± 0.093 (9.22) 
circGUCY1A2 24.68 (0.516) 1.461 (8.81) 24.68 ± 0.134 (0.541) 1.003 ± 0.092 (9.18) 
circLPP 25.71 (0.314) 1.177 (5.71) 25.76 ± 0.104 (0.406) 1.002 ± 0.070 (7.00) 
circNEAT1 35.56 (0.680) 1.285 (16.4) 36.80 ± 0.309 (0.838) 1.017 ± 0.214 (21.1) 
circRHOBTB3 23.91 (0.241) 1.055 (3.95) 24.02 ± 0.178 (0.739) 1.006 ± 0.121 (12.1) 
circSTIL 28.51 (0.542) 1.261 (10.9) 28.47 ± 0.105 (0.369) 1.002 ± 0.0.72 (7.18) 
linATXN10 20.23 (0.341) 1.250 (5.07) 20.21 ± 0.106 (0.525) 1.002 ± 0.072 (7.14) 
linCRIM1 21.67 (0.257) 1.305 (3.85) 21.49 ± 0.145(0.673) 1.004 ± 0.102 (10.1) 
linCSNK1G3 21.73 (0.275) 1.052 (4.13) 22.23 ± 0.152 (0.683) 1.003 ± 0.091 (9.08) 
linGUCY1A2 23.55 (0.480) 1.458 (8.22) 22.51 ± 0.134 (0.596) 1.004 ± 0.096 (9.57) 
linLPP 19.27 (0.472) 1.193 (6.64) 19.06 ± 0.121 (0.633) 1.003 ± 0.085 (8.46) 
linNEAT1 18.79 (0.231) 1.641 (2.96) 19.80 ± 0.079 (0.401) 1.001 ± 0.054 (5.38) 
linRHOBTB3 21.23 (0.259) 1.147 (3.73) 21.34 ± 0.170 (0.796) 1.006 ± 0.120 (11.9) 
linSTIL 25.88 (0.411) 1.381 (5.22) 26.22 ± 0.131 (0.500) 1.003 ± 0.089 (8.94) 
ALAS1 23.04 (0.305) 1.113 (4.86) 23.32 ± 0.064 (0.275) 1.001 ± 0.043 (4.33) 
HPRT1 25.32 (0.411) 1.192 (7.09) 25.97 ± 0.112 (0.432) 1.002 ± 0.077 (7.75) 
Abbreviations: Cq, quantification cycle; %RSD, percent relative standard deviation; SD, standard 
deviation; ALAS1, 5′-aminolevulinate synthase 1; HPRT1, hypoxanthine phosphoribosyltransferase 1. 
ALAS1 and HPRT1 were used as reference genes [81]. a n = 20; %RSD was calculated from duplicate 
measurements using the root mean square method based on Cq values and relative quantities, 
respectively. b n = 5 inter-assay measurements; %RSD (Cq) corresponds to the percent relative 
standard deviation using the Cq values. %RSD (Relative quantities) corresponds to the percent 
relative standard deviation using the relative quantities within the inter-assay measurements of the 
respective RNA variable. 
2.4. Clinical Assessment 
2.4.1. Differential Expression of circRNAs in Relation to Clinicopathological Variables 
In the first step, we compared the circRNA expression data obtained from the six paired tumor 
and adjacent normal tissue samples using microarray analysis and the established RT-qPCR assays 
(Table 4). The expression results were in good agreement between both measurement methods for 
the circRNAs, with the exceptions of circLPP and circSTIL. CircLPP and circSTIL were found to be 
upregulated in the microarray analysis but downregulated in RT-qPCR measurements. Despite this 
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clear discrepancy, we decided to include these two circRNAs together with their linear transcripts in 
further analyses. 
Table 4. Comparison of the circRNA expression data of the six paired tumor and adjacent normal 
tissue samples used in the microarray and RT-qPCR analyses. 
circRNA 
Microarray Expression Data a RT-qPCR Expression Data b 
Ratio of Tumor to Normal 
Tissue (p-Value) 
Ratio of Tumor to Normal 
Tissue (p-Value) 
circATXN10 −2.48 (0.001) −2.09 (0.020) 
circCRIM1 −2.17 (0.006) −2.45 (0.027) 
circCSNK1G3 −1.31 (0.003) −1.84 (0.027) 
circGUCY1A2 −1.02 (0.305) −1.07 (0.781) 
circLPP +1.94 (0.025) −2.01 (0.004) 
circNEAT1 +2.73 (0.024) +4.33 (0.061) 
circRHOBTB3 −2.14 (0.0003) −2.05 (0.041) 
circSTIL +1.75 (0.007) −1.35 (0.086) 
a Expression data correspond to the data shown in Table 2 (t-test of the six paired tissue samples used 
in microarray analyses). b Expression data of the paired samples used in the microarray analyses 
measured by the established circRNA assays in this study and normalized to the reference genes 
ALAS1 and HPRT1 (t-test of paired data). 
The expression levels of the circRNAs and their linear transcripts were measured and evaluated 
in all samples of the studied cohort (n = 194). To examine the differential expression between adjacent 
normal and malignant tissue samples, only the expression results of the paired samples of adjacent 
normal and malignant tissue samples were compared, in order to avoid bias due to biological 
variations between patients (Figure 4). Significant differential expression was observed between 
tumor and normal tissue samples, as indicated by T/N indices (Figure 4), for both circRNAs and their 
corresponding linear transcripts (Figure 4 and detailed in Table S8). The expression levels of all 
circRNAs except circNEAT1 and circGUCY1A2 were downregulated in tumor samples; circNEAT1 
was upregulated and the expression level of circGUCY1A2 did not differ between the two tissue 
samples. In contrast, only the linear transcripts linCRIM1 and linLPP were downregulated in the 
tumor samples, while linSTIL and linNEAT1 were upregulated, and linATXN10, linCSNK1G3, 
linGUCY1A2, and linRHOBTB3 showed no significant differences in expression between the normal 
and tumor tissue samples. 
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Figure 4. Expression levels of circular RNAs (circRNAs) and the linear transcripts of their host genes 
in tissue samples from prostate cancer (PCa) patients. The expression data of all eight circRNAs (A, 
C, E, G, I, K, M, O) and their corresponding linear transcripts (B, D, F, H, J, L, N, P) are shown in the 
matched pairs of adjacent normal tissue samples and malignant samples from PCa specimens 
collected by radical prostatectomy (n = 79, only 45 for circNEAT1 and linNEAT1). ALAS1 
(5′-aminolevulinate synthase 1) and HPRT1 (hypoxanthine phosphoribosyltransferase 1) mRNAs 
were used as stable expression normalizers of prostatic cancer [81]. Complete violin plots with the 
Int. J. Mol. Sci. 2020, 21, 7812 12 of 32 
 
entire expression ranges, the lower and upper quartiles (dashed lines), and the medians (bold lines) 
are presented. Statistically significant expression differences of the malignant tissue samples 
compared with the adjacent normal tissue samples are given as the T/N (tumor/normal) index. To 
facilitate a direct comparison of the expression results of each circRNA and its corresponding linear 
transcript in the tumor to normal tissue, we used the term T/N index. A positive number indicates a 
higher expression in tumor tissue (numerator in the index) in relation to normal tissue (denominator 
in the index) and a negative number shows a higher expression in the normal tissue (denominator in 
the index) in relation to tumor tissue (numerator in the index). 
Moreover, the following characteristics of the expression data were striking: (i) the upregulation 
of circLPP and circSTIL found in the microarray analysis could not be confirmed, as both circRNAs 
were shown to be downregulated in the RT-qPCR measurements, similarly to what was shown by 
the comparison of the paired samples used in the microarray analysis; (ii) all linear transcripts except 
circCSNK1G3 had significantly higher expression than their circRNAs. This can be seen on the x-axes 
of the corresponding panels and by the different ratios between the two tissue samples and the RNA 
types, as summarized in Tables S9 and S10. This was particularly remarkable for circNEAT1, which 
showed a low expression rate, with only 45 of the 79 examined pairs having detectable expression. 
Although the high number of biological replicates confirmed the increased expression of this 
circRNA in tumor tissue, circNEAT1 was not included in the further multivariable prognostic BCR 
analysis. This was also compatible with the less reliable analytical performance data of circNEAT1 
measurements in its low expression range, as mentioned above (Table 3), and the number of samples 
above the upper limit of the standard curve of this circRNA (Table S7). 
The expression data of all examined circRNAs and their linear transcripts in the tumor samples 
were not associated with age, preoperative PSA, prostate volume, digital rectal examination, tumor 
stage, and surgical margin status (Table S11). However, significant associations between the ISUP 
grade and all circRNAs except circNEAT1 and circRHOBTB3 were found, while only linGUCY1A2 
and linLPP showed such associations for the linRNAs. 
Close correlations between the expression levels of all circRNAs in both the adjacent normal and 
malignant tissue samples were observed, except for circNEAT1 and partly for circRHOBTB3 (Tables 
S12 and S13). However, these close correlations were mainly lost if data in matched normal tissue 
and malignant tissue samples were correlated (Table S14). Furthermore, there were several different 
correlation coefficients between circRNAs and the linear transcripts in malignant tissue samples in 
comparison to the matched adjacent normal tissue samples (Table S15). 
2.4.2. CircRNAs and linRNAs as Biomarkers for Discrimination between Normal and Cancerous 
Tissue 
The differences between the circRNAs and their linear transcripts described here support the 
idea, postulated in the introduction, that it makes sense to investigate circRNAs as cancer biomarkers 
in an integrative approach together with their linear transcripts, due to their potential differential 
influences in normal and cancerous tissue. From this point of view, the expression data of the 
circRNAs and linear transcripts were used to differentiate between adjacent normal and malignant 
tissue (Table 5). Data from the performed receiver operating characteristic (ROC) curve analysis 
revealed that circATXN10 and linSTIL were found to be the best individual markers for this purpose, 
with areas under the curves (AUCs) of 0.801 and 0.841, respectively. Using a backward elimination 
approach of binary logistic regression with all RNAs, a combined tool using these two markers 
resulted (Table 5). It is of particular interest that both RNAs were differentially expressed. 
CircATXN10 was downregulated in tumor samples, whereas linSTIL was upregulated. When 
applying the markers combined, the AUC value increased to 0.892. Both the ROC curve and the 
decision curve of this combination were found to run above the curves of the two individual markers 
(Figure 5). Thus, at least a “stabilizing” discriminative ability was achieved with the marker 
combination of circATXN10 + linSTIL. 
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Table 5. Receiver operating characteristic (ROC) curve analyses of circRNAs and their linear 
transcripts for discrimination between adjacent normal (n = 79) and malignant (n = 115) tissue samples 
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Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval. a 
The Youden index as a measure of overall diagnostic effectiveness is calculated by (sensitivity + 
specificity) - 1. b Significances between the AUC values of individual circRNAs and their linear 
counterparts. c Calculated by binary logistic regression using all RNAs in a backward elimination 
approach. Results are based on bias-corrected and accelerated bootstrap calculation with 2000 
iterations. 
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Figure 5. Receiver operating characteristic (ROC) curve and decision curve analyses of circATXN10 
and linSTIL as individual markers and in combination for discrimination between adjacent normal 
and malignant tissue samples. The data reflect the results shown in Table 5 for circATXN10, linSTIL, 
and their combination. 
2.4.3. CircRNAs and Linear Transcripts as Potential Markers for Predicting BCR 
BCR, as the selected clinical outcome endpoint, was defined as the time from the radical 
prostatectomy until the time of the corresponding event or the last follow-up. Detailed data for the 
patients with and without BCR at the time of follow-up after surgery are shown in Table 1. 
According to the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) 
[82], we used continuous data of the normalized relative expression quantities of the RNAs in the 
subsequently described Cox regression analyses. This procedure of using continuous data, if possible, 
is strongly recommended to avoid loss of information in detecting associations between cancer 
markers and time-dependent events [82]. The results of the univariable Cox regression analyses in 
this first step, which was done to evaluate the potential predictive validity of the total RNA panel, 
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are shown in Table 6. Those five circRNAs and three linear transcripts with p-values < 0.25 were 
selected for subsequent multivariable Cox regression analyses to avoid type II errors. So-called “full 
models”, including the respective circular and linear RNAs, and “reduced models” after a backward 
elimination (entry: p < 0.05, removal: p > 0.100) were separately constructed for the circRNAs and 
linRNAs (Table 6). 
Table 6. Construction of separate tools for prediction of biochemical recurrence using circRNAs and 
their linear counterparts. 
 Univariable Cox Regression a Multivariable Cox Regression 
RNA   Full Model b 
Reduced Model after 
Backward Elimination c 
 HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value 
Circular RNAs      
circATXN10 0.39 (0.10–1.88) 0.239 0.27 (0.08–0.89) 0.032 0.31 (0.13–0.76) 0.011 
circCRIM1 0.69 (0.22–2.16) 0.521 - - - - 
circCSNK1G3 2.32 (0.51–10.6) 0.240 1.96 (0.50–7.68) 0.336 - - 
circGUCY1A2 1.31 (0.98–1.75) 0.065 1.32 (0.99–1.75) 0.051 1.33 (1.02–1.74) 0.037 
circLPP 1.86 (0.84–4.12) 0.125 1.76 (0.78–3.96) 0.169 1.89 (0.91–3.95) 0.092 
circRHOBTB3 0.86 (0.38–1.93) 0.705 - - - - 
circSTIL 0.53 (0.18–1.53) 0.238 0.57 (0.21–1.62) 0.293 - - 
Linear mRNAs     - 
linATXN10 1.23 (0.15–10.2) 0.846 - - -- - 
linCRIM1 0.90 (0.22–3.76) 0.887 - - - - 
linCSNK1G3 0.47 (0.09–2.60) 0.399 - - - - 
linGUCY1A2 1.52 (0.99–2.32) 0.050 1.47 (1.09–2.00) 0.012 1.47 (1.09–2.00) 0.012 
linLPP 1.06 (0.23–4.76) 0.941     
linNEAT1 1.41 (1.15–1.72) 0.001 1.39 (1.16–1.66) 0.0003 1.39 (1.16–1.66) 0.0003 
linRHOBTB3 0.78 (0.20–3.11) 0.727     
linSTIL 0.59 (0.32–1.08) 0.086 0.54 (0.30–0.96) 0.037 0.54 (0.30–0.96) 0.037 
Abbreviations: HR, hazard ratio; CI, confidence interval. a As explained in chapter 2.4.1, circNEAT1 
was excluded from Cox regression analyses. b The full model included all variables of the univariable 
Cox regression with hazard ratios of p-values < 0.250. c Reduced model after backward elimination 
with entry p < 0.05 and removal p > 0.100. All data of the univariable and final multivariable Cox 
regression models are calculated by the bias-corrected and accelerated bootstrap method with 2000 
resamples. 
For the circRNAs, only circATXN10, circGUCY1A2, and circLPP remained in the reduced model, 
while for the linRNA-based model (linGUCY1A2, linNEAT1, and linSTIL), no further variables were 
eliminated by the backward approach. To estimate the capacity of these models to predict BCR, the 
C-statistic values were compared. The C-statistic results, given as the AUC ± SE of the prognostic 
indices calculated in the Cox regression analyses, did not differ between the full and reduced models 
for the circRNA-based BCR prediction (0.676 ± 0.055 vs. 0.649 ± 0.056, p = 0.219; details given in Table 
S16). The linRNA-based C-statistic value was found to be 0.722 ± 0.053, but it was also not statistically 
significant compared with the circRNA-based model (p = 0.141; details given in Table S16). However, 
a Cox regression analysis with eight RNA variables from the circRNA-based and linRNA-based “full 
models” or the six RNAs of the “reduced models” (Table 6) and a subsequent backward elimination 
showed that all circRNAs were excluded from the model (Table 7). Only three linRNAs—
linGUCY1A2, linNEAT1, and linSTIL—remained as independent variables in the model. This clearly 
shows that, compared to these linear RNAs, the circRNAs did not contribute to the BCR prediction. 
Thus, the model with linGUCY1A2, linNEAT1, and linSTIL, termed the “RNA signature” in the 
following text, was used as an additional tool for BCR prediction, together with clinicopathological 
factors. 
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Table 7. Construction of a predictive RNA signature for biochemical recurrence based on Cox 
regression analysis, using a combination of the separate prediction tools for circRNAs and their linear 
counterparts. 
 Multivariable Cox Regression of the Combined Separate RNA Classifiers 
RNA Prediction 
Tool 
Full Model with all Separate 
Classifiers a 
Reduced Model after Backward 
Elimination b 
 HR (95% CI) p-Value HR (95% CI) p-Value 
circRNA prediction tool   
circATXN10 0.45 (0.18–1.12) 0.086 not included - 
circGUCY1A2 0.95 (0.55–1.64) 0.850 not included - 
circLPP 1.37 (0.66–2.82) 0.399 not included - 
linear RNA prediction tool  
linGUCY1A2 1.77 (0.80–3.89) 0.153 1.47 (1.09–2.00) 0.012 
linNEAT1 1.33 (1.11–1.60) 0.002 1.39 (1.16–1.66) 0.0003 
linSTIL 0.52 (0.29–0.94) 0.030 0.54 (0.30–0.96) 0.037 
Abbreviations: HR, hazard ratio; CI, confidence interval. a This model included all six RNA variables 
indicated in Table 6 as the “Reduced model after backward elimination” of the separate circRNA and 
linear RNA based prediction tools. b Reduced model after backward elimination with entry p < 0.05 
and removal p > 0.100. All data of the univariable and final multivariable Cox regression models are 
calculated by the bias-corrected and accelerated bootstrap method with 2000 resamples. 
To assess the validity of our linear transcript data regarding the BCR prediction, we used The 
Cancer Genome Atlas Prostate Cancer (TCGA-PRAD) dataset, a publicly available dataset (Table 
S17). This dataset contains information from 427 patients and includes 89 cases of BCR, defined as a 
re-increase of PSA > 0.2 µg/L after prostatectomy, as in our study cohort. Univariable Cox regression 
analyses of the linear transcripts showed that increased expression of linSTIL was closely associated 
with BCR, as in our study, whereas statistically significant relationships of the other transcripts with 
BCR were not observed (Table S17). 
2.4.4. BCR Prediction Models Based on Clinicopathological Variables in Combination with the RNA 
Signature 
As briefly outlined in the introduction, different tools for predicting BCR based on the 
clinicopathological variables have been introduced in clinical practice. It was therefore of interest to 
(i) compare the predictive potential of the RNA signature elaborated above with the results of such 
clinical models and (ii) evaluate whether a combination of both approaches could improve the 
prognostic accuracy of single tools. 
For this purpose, based on univariable and multivariable Cox regression analyses of the 
clinicopathological variables in our study cohort, we constructed full and reduced models to predict 
the occurrence of BCR (Table 8). 
Table 8. Construction of a predictive classifier for biochemical recurrence using Cox regression 
analyses with clinicopathological variables in 115 patients. 
Variable a 
Univariable Cox Regression Multivariable Cox Regression 
  Full Model b 
Reduced Model after 
Backward Elimination c 
 HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value 
Age 0.97 (0.93–1.02) 0.280     
PSA (> 10 <) 2.24 (1.18–4.18) 0.0130 1.59 (0.83–3.07) 0.162   
DRE 1.24 (0.83–1.95) 0.286     
Margin 2.37(1.24–4.52) 0.009 1.91 (0.98–3.72) 0.056 1.99 (1.03–3.84) 0.041 
pN status 2.60 (0.92–7.35) 0.071 0.58 (0.19–1.81) 0.352   
pT stage 2.16 (1.51–3.09) <0.0001 1.55 (1.03–2.33) 0.037 1.58 (1.05–2.40) 0.030 
ISUP Group 1.66 (1.31–2.11 <0.0001 1.55 (1.14–2.10) 0.005 1.43 (1.07–1.91) 0.016 
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a Abbreviations and stratifications of the variables as indicated in Table 1; CI, confidence interval; HR, 
hazard ratio. b The full model included all variables of the univariable Cox regression with hazard 
ratios of p < 0.250. c Reduced model after backward elimination with entry p < 0.05 and removal p > 
0.100. All data of the univariable and final multivariable Cox regression models are calculated by the 
bias-corrected and accelerated bootstrap method with 2000 resamples. 
In addition, the established predictive BCR reference models CAPRAS [9] and NCCN [11] as 
well as those according to D’Amico et al. [10] and Stephenson et al. [7] were used. In all cases, the C-
statistic values of the obtained prognostic indices were calculated using purely clinicopathological-
based tools combined with the RNA signature (Table 9). As mentioned above, the C-statistic value of 
the RNA signature with linGUCY1A2, linNEAT1, and linSTIL was 0.722 ± 0.053 (95% CI: 0.631–0.801), 
which was only significantly higher than D’Amico et al.’s reference model value of 0.513 (95% CI: 
0.418–0.607; p = 0.003). There were no statistical differences compared with the other 
clinicopathological tools listed in Table 9 (p-values between 0.128 and 0.640). However, the 
combination of the RNA signature with individual clinicopathological-based prediction tools 
increased the C-statistics values of all clinicopathological-based tools (Table 9). This was especially 
statistically significant for the tools presented by D’Amico et al. [10], CAPRAS [9], and NCCN [11]. 
In addition, decision curve analyses of our elaborated full model and the other four 
clinicopathological-based reference models were performed in combination with the RNA signature 
(Figure S4). The improved prediction of BCR by this inclusion of the RNA signature was confirmed, 
as the corresponding curves generally ran above the individual curves of the clinicopathological-
based tools (Figure S4). 
Table 9. Improved prediction of biochemical recurrence after radical prostatectomy using 





Tool Combined with RNA 
Signature 
p-Value 
 AUC (95% CI) AUC (95% CI)  
Present study 
Full model 0.810 (0.726–0.877) 0.841 (0.761–0.902) 0.073 
Reduced model 0.804 (0.720–0.872) 0.827 (0.746–0.891) 0.104 
Reference models 
D’Amico et al. [10] 0.513 (0.418–0.607) 0.718 (0.627–0.798) 0.004 
CAPRAS [9] 0.750 (0.660–0.826) 0.799 (0.714–0.868) 0.034 
NCCN [11] 0.733 (0.643–0.811) 0.800 (0.715–0.869) 0.035 
Stephenson et al. [7] 0.785 (0.699–0.856) 0.821 (0.738–0.886) 0.107 
Abbreviations: AUC, area under the receiver operating characteristic curve as C-statistics calculated 
from the prognostic indices of the Cox regression analyses; CI, confidence interval; CAPRAS, Cancer 
of the Prostate Risk Assessment Postsurgical Score; NCCN, National Comprehensive Cancer 
Network; Full model, according to the Cox regression model described in Table 8 with all 
clinicopathological factors except of age and digital rectal examination; Reduced model, according to 
the Cox regression model described in Table 8 after backward elimination and finally including only 
the variables of pT stage, ISUP Group grade, and surgical margin status. Results are based on bias-
corrected and accelerated bootstrap calculation with 2000 iterations. 
3. Discussion 
In this retrospective study with three working phases (Figure 1), we identified differentially 
expressed circRNAs in PCa tissue samples using microarray analysis, performed an analytical 
validation of eight selected circRNAs and their linear counterparts via RT-qPCR measurements, and 
successfully elaborated RNA-signatures as discriminative biomarkers to differentiate between 
normal and cancerous PCa tissue and as predictive BCR biomarkers. This information was combined 
with clinicopathological variables to improve the prediction of BCR. 
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For the genome-wide identification of circRNAs in PCa tissue, we used six paired PCa tissue 
samples in the discovery phase in a microarray approach. Generally, microarray analysis is 
considered a strong and reliable tool for predicting circRNA profiles in clinically relevant tissue 
samples [83]. However, compared with high-throughput circRNA sequencing analysis with its 
discovery potential for new cirRNAs, microarray platforms have the drawback of only including a 
limited number of already validated circRNAs [84]. The microarray analysis identified 43 
upregulated and 134 downregulated circRNAs with a higher than absolute 1.5-fold change in 
malignant tissue samples (Figure 2C). For further evaluation, we chose three upregulated (circLPP, 
circSTIL, and circNEAT1) and three downregulated (circATXN10, circCRIM1, and circRHOBTB3) 
circRNAs based on their differential expression levels identified in the microarray analysis and in an 
in silico circRNA-miRNA-gene interaction analysis (Supplementary Information S2 (Supplementary 
Materials) with Figure S1). In addition, circCSNK1G3 and circGUCY1A2 were included in this panel 
for control purposes, since they had already been investigated by other working groups at the start 
of our study [44,45]. Furthermore, in order to correlate our results with the linear products of the 
circRNA host genes in an integrative approach, we included the linRNA counterparts of the 
circRNAs in this study. 
After successful experimental validation of the circular feature of the selected circRNAs and the 
establishment of their fit-for-purpose RT-qPCR assays (Section 2.3), a comparison of the microarray 
and RT-qPCR data of the eight circRNAs showed discrepant results for circSTIL and circLPP (Table 
4). For the other examined circRNAs, the results of the RT-qPCR and microarray analyses were found 
to be congruent. The downregulation of circSTIL and circLPP in the malignant vs. adjacent normal 
PCa tissue samples was confirmed via RT-qPCR measurements of the 79 paired samples (Figure 4). 
Inconsistent differential expression of circRNAs in microarray or sequencing vs. in the RT-qPCR 
analyses has also been observed in previous studies of PCa and other cancers. Shan et al. [85] 
identified consistent expression between microarray and RT-qPCR analyses in four of five selected 
circRNAs using 90 PCa and paired non-cancerous tissue samples. Yan et al. [86] reported that three 
of four selected circRNAs in PCa cells analyzed by RT-qPCR showed consistent high-throughput 
sequencing results. Qui et al. [87] found an upregulation of circCASP8AP2 in hepatocellular 
carcinoma compared to adjacent normal tissue by sequencing, but in RT-qPCR analyses, this circRNA 
was downregulated. The reason for these discrepancies between microarray/sequencing data and 
RT-qPCR results is not clear. Since the same samples were used for the different analytical techniques, 
it can be assumed that there can only be analytical or post-analytical reasons for these results [31]. 
The use of different normalization approaches, dependence on the digestion effect of RNase R on 
circRNAs and linear mRNAs, and method-dependent effect of RNA integrity on the measurement 
results might be the reasons for these discrepancies [88–91]. Considering these aspects, the expression 
evaluation of circRNAs in isolated total RNA samples using RT-qPCR measurements combined with 
validated cancer-specific reference genes, as done in the present study, might be a practical way to 
minimize such discrepancies [88]. Further research is needed in this respect, but this was beyond the 
scope of this study. Furthermore, regarding these discrepancies, the inconsistent results reported for 
the same circRNAs when examined in different studies should be mentioned. For example, Kong et 
al. [92] found that hsa_circ_0006404 was upregulated in 53 paired PCa samples. In contrast, Shen et 
al. [48] showed that the same circRNA was downregulated in 22 low-grade and 22 high-grade PCa 
tissue samples in comparison with 18 normal prostate tissue samples. In addition to the above-
mentioned possible analytical and post-analytical reasons, different clinicopathological 
characteristics of the investigated study cohorts, but also pre-analytical interferences due to the 
different “quality” of the tissue samples used in different studies may be responsible for these 
differences [88]. 
The comparison of the expression levels of circRNAs and linRNAs in the 79 paired PCa tissue 
samples revealed interesting relationships (Figure 4). Here, we found that all linRNAs except for 
linCSNK1G3 had significantly higher expression levels than the circular RNAs. This observation was 
concordant with results shown in earlier circRNA studies [23,24,93]. Additionally, circSTIL showed 
significantly lower expression in tumor samples than in normal tissue samples, while linSTIL was 
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significantly higher expressed in tumor samples. Moreover, the normalized expression of linNEAT1 
was nearly 17,000-fold higher than the expression level of circNEAT1 (Figure 4 and Table S10), while 
the ratio between tumor and normal tissue was equal for both RNAs (circNEAT1: +1.70 vs. linNEAT1: 
+1.75). A possible explanation for the high linRNA expression could be the similarly abundant 
expression of the lncRNA NEAT1 (lncNEAT1) in PCa, which may be an indicator of the independent 
expression of circRNAs and linRNAs/lncRNAs [94,95]. However, because of the limited performance 
data from the circNEAT1 RT-qPCR analyses and the incomplete detection of this analyte in all 
samples, we did not include this circRNAs in the multivariable analyses. Nevertheless, more 
analytically sensitive quantification techniques like the droplet digital polymerase chain reaction 
should be used to allow this circRNA to be included in future studies. 
The differential expression of the malignant and adjacent normal tissue samples identified 
circATXN10 and linSTIL as strong biomarkers in terms of differentiating between tumor and normal 
tissue. The AUC value for these two markers combined was 0.892 (95% CI: 0.834–0.925). The decision 
curve analysis also showed a higher discriminative ability when combining circATXN10 and linSTIL, 
compared with applying them alone (Figure 5). Xia et al. [47] evaluated the diagnostic potential of 
the two circRNAs circ_0057558 and circ_0062019 in PCa. When applying these two circRNAs in 
combination, an AUC value of 0.861 was achieved. Another working group identified 
hsa_circ_0001633, hsa_circ_0001206, and hsa_circ_0009061 as possible discriminative tissue 
biomarkers with respective AUCs of 0.809, 0.774, and 0.711 [58]. Although these results are 
promising, the ability of circRNAs to differentiate between malignant and non-malignant tissue in 
other cancer types is much higher. In a recent study on circRNAs in clear cell renal cell carcinoma, 
we identified circEGLN3 (hsa_circ_0101692) as a strong marker for differentiation between normal 
and cancerous tissue, with an AUC of 0.98 when used alone and an AUC of 0.99 when combined with 
its linear counterpart [22]. Nevertheless, in the future, circRNAs might be used as components of a 
molecular pattern to improve diagnostic accuracy in the pathological evaluation of cancerous tissue 
and to provide possible helpful information on the development processes of cancer. 
The associations of circRNAs and linRNAs with each other and with standard 
clinicopathological variables is of special interest. The following distinctive features were 
noteworthy: (i) the expressions of all circRNAs were found to be strongly correlated in both the 
adjacent normal and malignant tissue samples, except for circNEAT1 and partly for circRHOBTB3, 
while this correlation feature was mainly lost between paired samples (Tables S12–S14); (ii) different 
correlation coefficients between circRNAs and the linear transcripts were observed in paired 
malignant and normal tissue samples (Table S15); and (iii) all circRNAs except circNEAT1 and 
circRHOBTB3 were significantly correlated with the ISUP grade but not with other relevant 
clinicopathological variables such as preoperative PSA, the tumor stage, and the surgical margin 
(Table S11). Thus, in comparison with other studies that examined other circRNAs [44,51,58–62], few 
associations with generally relevant clinicopathological PCa variables were identified. This is by no 
means a primary disadvantage with regard to their potential clinical validity as prognostic/predictive 
markers. In contrast, this expression of RNAs mostly independent from clinicopathological variables 
and the other mentioned particular correlations is a key characteristic of orthogonal biomarkers [96]. 
Biomarkers of this kind are a real prerequisite for gaining information additional to that derived from 
established variables and for improving, for example, the prediction accuracy of a clinical outcome 
endpoint [97]. 
In the introduction, we described the aim of this study as being to evaluate the clinical validity 
of circRNAs and their linear transcripts with regard to BCR after radical prostatectomy. The essential 
problems in this respect were explained and need not be repeated, but it should be stressed that data 
on circRNAs and BCR are lacking. It was therefore particularly important to follow the REMARK 
guidelines, which recommend the use of continuous expression data in Cox regression analyses as 
predictive variables of an endpoint and the rejection of primary dichotomized data applications [82]. 
This study investigated the ability of the circRNAs and linear transcripts to predict BCR occurrence 
alone and in combination with clinicopathological variables in a step-by-step process. CircATXN10, 
circGUCY1A, and circLPP remained after a multivariable Cox regression analysis of the examined 
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circRNAs with backward elimination in a model of BCR prediction (Table 6). On the other hand, in 
combination with the linear RNAs, these circRNAs were eliminated in the multivariable Cox 
regression analysis and thus were found to have no role in BCR prediction in comparison to the 
linRNAs. Only linGUCY1A2, linNEAT1, and linSTIL were identified as relevant BCR predictor 
variables, and these were subsequently termed the “RNA signature” (Table 7). This result is by no 
means surprising. By comparing circRNA expression with the expression of linear counterparts, the 
independent clinical value of circRNAs and linear transcripts has already been reported in other 
studies [44,98]. Therefore, it makes sense to take this functional aspect into account in an integrative 
approach by simultaneously determining circRNAs and their linear transcripts. Loss of information 
could thus be avoided. However, this requires that RT-qPCR determinations, as in our study, are 
performed on isolated total RNA without RNase R pretreatment and that validated reference genes 
are used to normalize relative expression quantities. This problem was also recently highlighted 
when the database MiOncoCirc was introduced [39]. The authors recommended the use of a special 
capture exome RNA-sequencing protocol without RNase R pretreatment [99] in order to determine 
the actual relationship between circRNA and linRNA in the tissue [39]. 
Furthermore, the linRNAs were evaluated as BCR predictors in a univariable Cox regression 
analysis with the TCGA dataset (Table S17). Especially noteworthy was linSTIL, which was found to 
be significantly associated with the risk of BCR. In contrast, circCSNK1G3, which was selected by 
Chen et al. [44] as an example for demonstration of its functional mechanisms, was not found to be a 
relevant BCR predictor in our study (Table 6) or in the TCGA dataset (Table S17). 
To assess the clinical validity of this final RNA signature, we compared the C-statistic data of 
the prognostic indices of the RNA signature with those of four established models frequently used in 
clinical practice and our developed model based on using only clinicopathological variables. The C-
statistic data of the RNA signature did not differ from those of established clinical models, except for 
the model developed by D’Amico et al. [10], which showed statistically significantly lower values. 
However, most importantly, when the clinical models were combined with the RNA signature, 
statistically significant improvements in the BCR predictive accuracy or at least corresponding 
tendencies were evident (Table 9). This improved predictive accuracy was confirmed by decision 
curve analyses (Figure S4). Decision curve analysis has been postulated as the most informative 
metric for an incremental predictive benefit [100]. These results support the view that there is 
considerable potential for improvement of the current prognostic models based only on 
clinicopathological factors by including molecular RNA markers [17–21]. Recently, the NCCN 
Prostate Cancer Guideline Panel suggested that tissue-based tests like Decipher, OncoType, Dx 
Prostate, Prolaris, and ProMark could be considered for initial PCa risk assessment [101]. 
Of the 16 RNAs examined, a total of six RNAs were represented in the combined models after 
ROC and multivariable Cox regression analyses (Tables 5 and 6). These were circATXN10 and linSTIL 
as tissue differentiation markers and BCR predictors (Table 5 and Table 6), and circGUCY1A2 and its 
linear counterpart, circLPP, and linNEAT1 for BCR prediction. As explained above, ultimately only 
linGUCY1A2, linNEAT1, and linSTIL remained in the final model as the RNA signature for BCR 
prediction. So far, there are few data on the listed RNAs in the context of PCa and other cancers. 
Expression data that could be used for the differentiation of tissue samples as well as BCR markers 
are missing. Reference to possible biological functions has only been made in few cases, and the 
validity as a biomarker has only been considered for linNEAT1 [95]. Since our intention in this study 
was primarily to investigate the clinical validity of the selected RNAs as possible biomarkers, we 
deliberately refrained from undertaking functional investigations. Furthermore, the clinical validity 
of a marker and thus its applicability in a clinical setting is not primarily linked to its functional 
significance [102]. The development of an applicable biomarker should focus on demonstrating a 
benefit in comparison to the methods used to date [79]. To formulate this opinion in exaggerated 
terms, only proof of the meaningful use of a biomarker for a specific clinical problem should be a 
justified reason to characterize its possible biological background experimentally. Thus, a brief 
summary of the current state regarding the biological backgrounds of the relevant RNAs identified 
herein as potential biomarkers is given to provide directions for future work. 
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In detail, this is as follows: 
CircATXN10 has not yet been discussed in connection with cancer. Our data here represent the 
first results in this area. 
CircGUCY1A2 was found to be of particular importance in PCa pathogenesis in an investigation 
of various PCa cells based on differential expression and bioinformatics information [45]. 
Experimental findings and data on human PCa tissue samples, as well as on linGUCY1A2, are not yet 
available. In this respect, our data represent the first information in this area. 
For linSTIL, Wu et al. [63] found increased expression in PCa tissue, similar to the results of our 
study. In cell experiments, these linSTIL changes were shown to be responsible for stimulating the 
proliferation of PCa cells and suppressing apoptosis through interactions with various signaling 
pathways. An investigation on gastric cancer confirmed these effects of upregulated linSTIL [103]. 
CircLPP has not yet been investigated in PCa or other cancers regarding to its biological 
functions or its potential as a biomarker. Reduced expression of the host gene has been described in 
lung cancer, similar to the results of the present PCa study [66]. Cell culture experiments on myeloma 
cells showed that a loss of LPP leads to the upregulation of N-cadherin, subsequently promoting 
tumor cell invasion and metastasis through epithelial-mesenchymal transition. 
LinNEAT1 has been described in some studies as upregulated mRNA with different oncogenic 
effects on PCa cells. In PCa, it promotes the expression of the oncogene HMGA2 through the sponging 
of miR-98-5p, as well as leading to docetaxel resistance by sponging miR-34a-5p and miR-204-5p 
[65,104]. Furthermore, NEAT1 promotes the proliferation of PCa cells in connection with the steroid 
receptor co-activator (SCRC3) through the insulin-like growth factor 1 receptor/AKT serine/threonine 
kinase 1 (IGF1R/AKT) signaling pathway [105]. As shown in the present study using BCR as the 
clinical endpoint, Bai et al. [95] reported increased expression of NEAT1 mRNA as being an 
independent prognostic factor for overall patient survival. 
Despite our efforts to make this study as comprehensive and bias-free as possible, particularly 
taking into account the REMARK, MIQE, and STARD guidelines, it had inherent limitations. These 
include the retrospective nature of this study, the lack of external validation, and the choice of BCR 
as an endpoint without consideration of alternative clinical endpoints such as metastasis-free survival 
or cancer-specific survival. On the other hand it should be emphasized that our data calculated with 
the bootstrapping method as preferable approach for internal validation [106] confirmed the 
reliability of results obtained with the constructed models in this study. 
4. Materials and Methods 
4.1. Patients and Tissue Samples 
The Ethics Committee of the Charité-University Medicine Berlin approved the study 
(EA1/134/12; approval date: 22 June 2012). Informed consent was obtained from all patients. The 
study was performed in accordance with the Declaration of Helsinki. Corresponding study 
guidelines (Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
(MIQE), Updated List of Essential Items for Reporting Diagnostic Accuracy Studies (STARD 2015), 
and Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)) were taken into 
account [76,79,82]. 
Tissue samples from PCa patients undergoing radical prostatectomy were snap-frozen in liquid 
nitrogen immediately after surgery and stored at −80 °C or were immediately transferred into 
RNAlater stabilization reagent (Qiagen, Hilden, Germany) and stored at −20 °C until RNA isolation 
as described previously [81,107,108]. Tumor staging and grading (Table 1) was reviewed by two 
experienced uropathologists (E.K., S.E.) according to the criteria of the International Union against 
Cancer (UICC TNM, 8th edition) and the World Health Organization/International Society of 
Urological Pathology (WHO/ISUP) [109,110], respectively. 
  
Int. J. Mol. Sci. 2020, 21, 7812 22 of 32 
 
4.2. Analytical Methods 
4.2.1. Total RNA Samples and Their Characteristics 
Total RNA was isolated from tissue pieces of 31 mg (median value, 95% CI: 30–32) collected from 
the abovementioned preserved tissue specimens using a special punch-bioptic technique as reported 
in our previous publications [108,111,112]. This procedure allows to obtain tumor tissue (>90%) and 
matched normal tissue completely free of tumor filtrates and without inflammation or atrophy. 
Prominent inflammatory infiltrates, lack of epithelium due to stromal hyperplasia, and prostatic 
intraepithelial neoplasia were used as exclusion criteria. Taking into account these criteria, a largely 
bias-free comparison of the expression data between the adjacent normal and malignant tissue 
samples can be considered. The miRNeasy Mini Kit (Qiagen, Hilden, Germany) with an on-column 
DNA digestion step, according to the producer’s instructions, was used for total RNA isolation 
[107,108,112]. Spectrophotometric quantification and quality assessment of the total RNA samples 
were performed using the NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA) and the Bioanalyzer 2100 with the Agilent RNA 6000 Nano Chip Kit (Agilent 
Technologies, Santa Clara, CA, USA), as detailed reported in our previous publications [81,107,108]. 
The RNA samples, isolated with 30 µL nuclease-free water, showed the following characteristics: a 
median absorbance ratio at 260 to 280 nm of 2.12 (95% CI: 2.12 to 2.13), a median absorbance ratio at 
260 to 230 nm of 1.99 (95% CI: 1.97 to 2.03), a median RNA integrity number (RIN) value of 7.00 (95% 
CI: 6.90 to 7.20), and a median RNA concentration of 1096 ng/µL (95% CI: 1001 to 1214). RNA samples 
were stored at −80 °C. Further details are listed in the checklist of the MIQE guidelines (Table S1). 
4.2.2. Microarray Detection of circRNAs 
Using isolated total RNA samples from six paired adjacent normal and malignant tissue samples 
of PCa specimens (1× pT3a with ISUP 2, 1× pT3b with ISUP 2, 2× pT3a with ISUP 3, 2× pT3b with 
ISUP 3), microarray analyses were performed as a custom order by ArrayStar Inc. (Rockville, MD, 
USA), as previously reported [22]. Briefly, RNA samples were digested with RNase R to destroy 
linear RNAs and enrich circular RNAs. Afterwards, the circRNAs were amplified, transcribed, 
fluorescently labeled, and hybridized on the ArrayStar Human Circular RNA Array. This array is 
designed to detect 13,617 circRNAs. The Agilent scanner (G2505C) and softwares (Agilent Feature 
Extraction software version 11.0.1.1 and Agilent GeneSpring GX) were used for imaging scanning 
and analysis. Quantile normalization was used to normalize the obtained probe intensities. The R 
Bioconductor “limma” package was applied to calculate the differential expression between the 
matched pairs. All data were compiled in the accompanying separate Excel file with all additional 
information and annotation details (Supplementary Microarray Data File.xlsx (Supplementary 
Materials)). 
4.2.3. RT-qPCR Methodology and circRNA Validation Methods 
RT-qPCR measurements were performed according to the recommendations in the MIQE 
guidelines [76]. The corresponding comments are listed in the abovementioned checklist of the MIQE 
guidelines and applied for all assays (Supplementary Information S3 with Table S1 and the additional 
Tables S2–S7). 
Detailed validation procedures based on the general characteristics of circRNAs regarding their 
resistance to RNase R digestion, their lack of a poly(A) tail using separate reverse transcription with 
random hexamer and oligo(dT)18 primers, and the proof of the backsplice junctions by Sanger 
sequencing, were described in our previous report on circRNAs in kidney cancer [22] and are briefly 
summarized in Supplementary Information S4 to explain the data in Figure 3. A melting curve 
analysis and gel electrophoresis were additionally carried out as confirmatory approaches to verify 
the analytical specificity of the RT-qPCR products of all circRNAs (Figures S2 and S3). 
The Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Fisher Scientific, Waltham, 
MA, USA; Cat.No. K1642) was used for cDNA synthesis of circRNAs and their linear counterparts, 
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as this kit contains a ready-to use mixture of random hexamer and oligo(dT)18 primers (Table S2A). 
For the validation of circRNAs, we addressed the issue of reliability of reverse transcription using 
another cDNA synthesis kit (Transcriptor First Strand cDNA Synthesis Kit, Life Science Roche, 
Mannheim, Germany; Cat. No. 04379012001) that allows separate priming with either random 
hexamer or oligo(dT)18 primers (Table S2B). 
The LightCycler 480 Instrument (Roche Molecular Diagnostics, Mannheim, Germany) with 
white 96-well plates (Cat.No. 04729692001) and a reaction volume of 10 µL was used for all real-time 
qPCR runs. The Maxima SYBR Green qPCR Master Mix (Thermo Fisher Scientific; Cat.No. K0252) 
was used. Primers were designed using the blasting tool provided by Primer3 [113] and synthesized 
by TIB MOLBIOL GmbH (Berlin, Germany). The reaction conditions with the list of primers, 
measurement details, setup of the assays, and performance data for all eight circRNAs and their 
linear counterparts as well as the reference genes ALAS1 and HPRT1 as a combined pair for 
normalizing expression data in PCa samples [81] are compiled in Table S6 with the protocols A–I. 
No-template controls and no-reverse transcriptase controls were always included and showed 
negative results. All cDNA samples were measured at least in duplicate and the resulting mean 
values of the quantification cycles were used for further calculations. 
The software qBase+ version 3.2 (Biogazelle, Zwijnaarde, Belgium; www.qbaseplus.com) was 
used for Cq data evaluation [114,115]. This program is based on a generalized model of the 2-ΔΔCq 
approach with correction of the amplification efficiency. Cq values were converted into relative 
quantities (RQs) with respect to equal amounts of total RNA for all samples used for the cDNA 
synthesis, and they were converted into normalized relative quantities (NRQs) based on the 
expression of the two cancer-specific reference genes mentioned above, ALAS1 and HPRT1. 
4.3. Statistics and Data Analysis 
The statistical programs SPSS Version 25 (IBM Corp., Armonk, NY, USA) with the bootstrap 
module, GraphPad Prism version 8.4.3 (GraphPad Software, La Jolla, CA, USA), and MedCalc 
version 19.4. (MedCalc Software bvba, 8400 Ostend, Belgium) with bootstrapping C-statistics were 
used. p < 0.05 (two-sided) represented statistical significance. The Mann-Whitney U-test, Wilcoxon 
test, t-test, and Spearman rank correlation coefficients were used for continuous data and Chi-
squared or Fisher’s exact tests were used for categorical data. Univariable and multivariable Cox 
proportional hazard regression analyses were used for survival analysis of the endpoint BCR. C-
statistic values based on ROC analyses with AUC calculation of prognostic indices of Cox regression 
analyses and corresponding decision curve analyses were determined to characterize the 
discrimination/prediction capacity of the different variables and models [116–119]. Sample size and 
power calculations were performed using the programs GPower version 3.1.9.4 [120], GraphPad 
StatMate version 2.0 (GraphPad Software), and MedCalc version 19.4 (MedCalc Software bvba), and 
the results were used to design the study. The prediction tool CircInteractome [69] was used for the 
in silico analysis of circRNAs to identify potential miRNA-gene interactions using the miRDB and 
TargetScan databases [70,71]. TCGA-PRAD RNAseq data were downloaded and analyzed with R 
(version 3.6) using the “TCGA2stat” library and the “survival” library for univariable Cox regression 
analyses of the linear counterparts of the eight circRNAs. 
5. Conclusions 
This study investigated the value of circRNAs and their linear counterparts as potential 
diagnostic and prognostic biomarkers in PCa using a genome-wide, integrative, and exploratory 
approach. We showed that the combination of circATXN10 and linSTIL provides a strong marker 
pair that can be used to discriminate between normal and malignant PCa tissue samples. 
Furthermore, we identified linGUCY1A2, linNEAT1, and linSTIL as potentially useful prognostic 
biomarkers to increase the accuracy of BCR prediction in PCa patients in combination with standard 
risk prediction models based only on clinicopathological variables. These results support the thesis 
that there is considerable potential to improve the current clinical prognostic models by including 
molecular RNA markers. In future studies, it will be advantageous to include circRNAs into the 
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clinicogenomic models in addition to the established RNA classes such as miRNA, mRNA, piwiRNA 
or lncRNA. 
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%RSD percent relative standard deviation 
AKT AKT serine/threonine kinase 1 
ALAS1 5′-aminolevulinate synthase 1 
ATXN10 ataxin 10 
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AUC area under the ROC curve 
BCR biochemical recurrence 
CAPRAS Cancer of the Prostate Risk Assessment Postsurgical Score 
cDNA complementary DNA 
CI confidence interval 
circ circular (used in composition with gene symbols to define examined circRNAs) 
circRNA circular RNA 
Cq quantification cycle 
CRIM1 cysteine rich transmembrane BMP regulator 1 
CSNK1G3 casein kinase 1 gamma 3 
DRE digital rectal examination 
GUCY1A2 guanylate cyclase 1 soluble subunit alpha 2 
HPRT1 hypoxanthine phosphoribosyltransferase 1 
HR hazard ratio 
IGF1R insulin like growth factor 1 receptor 
IQR interquartile range 
ISUP International Society of Urologic Pathology 
lin lin (in composition with gene symbols to define examined linRNAs) 
linRNA linear RNA (mRNA) 
lnc long non-coding (used in composition with gene symbols) 
LPP LIM domain containing preferred translocation partner in lipoma 
MIQE 
The Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments 
NCCN National Comprehensive Cancer Network 
NEAT1 nuclear paraspeckle assembly transcript 1 
NRQ normalized relative quantity 
PCa prostate cancer 
pN pathological lymph node status 
PSA prostate-specific antigen 
pT pathological tumor classification 
REMARK Reporting Recommendations for Tumor Marker Prognostic Studies 
RHOBTB3 rho related BTB domain containing 3 
RIN RNA integrity number 
ROC receiver operating characteristic 
RQ relative quantity 
RT-qPCR reverse-transcription quantitative real-time polymerase chain reaction 
SCRC3 steroid receptor co-activator 
STARD Standards for Reporting of Diagnostic Accuracy Studies 
STIL STIL centriolar assembly protein 
TCGA (PRAD) The Cancer Genome Atlas Prostate Cancer 
T/N expression index of circRNA or linRNA in tumor to adjacent normal tissue 
TNM Tumor, Node, Metastases 
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